Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 901 to 915 of 1560 results for do not do recommendations

  1. Effectiveness and cost effectiveness of drug misuse prevention interventions for groups vulnerable to drug misuse:- What is the effectiveness and cost effectiveness of drug misuse prevention interventions for groups vulnerable to drug misuse in the UK?

    Recommendation ID NG64/3 Question Effectiveness and cost effectiveness of drug misuse prevention interventions for groups vulnerable to

  2. Bortezomib monotherapy for relapsed multiple myeloma (TA129)

    Evidence-based recommendations on bortezomib monotherapy (Velcade) for treating relapsed multiple myeloma in adults.

  3. What is the effectiveness, cost effectiveness and acceptability of the whole family approach to carers' assessments?

    Recommendation ID NG150/1 Question What is the effectiveness, cost effectiveness and acceptability of the whole family approach to...

  4. Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency (TA709)

    Evidence-based recommendations on pembrolizumab (Keytruda) for treating metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency in adults.

  5. Our research work

    Our science policy and research programme team produces high-quality, impactful research.

  6. Recommendation 1 Research studies and trials. Who should take action? Research councils, commissioners and funders.

    Recommendation ID PH47/1 Question Recommendation 1 Research studies and trials. Who should take action? Research councils,...

  7. Recommendation 4 Weight management programmes. Who should take action? Research councils, commissioners and funders. Researchers and investigators.

    Recommendation ID PH47/4 Question Recommendation 4 Weight management programmes. Who should take action? Research councils,...

  8. Apremilast for treating moderate to severe plaque psoriasis (TA419)

    Evidence-based recommendations on apremilast (Otezla) for treating moderate to severe plaque psoriasis in adults.

  9. Midcarpal hemiarthroplasty for wrist arthritis (HTG529)

    Evidence-based recommendations on midcarpal hemiarthroplasty for wrist arthritis in adults. This involves using a metal implant to create an artificial wrist joint, to relieve pain and maintain movement.

  10. Transcatheter aortic valve implantation (TAVI) for native aortic valve regurgitation (HTG752)

    Evidence-based recommendations on transcatheter aortic valve implantation (TAVI) for native aortic valve regurgitation. This involves implanting a replacement valve inside the faulty native valve.

  11. Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma in people 3 years and over (TA967)

    Evidence-based recommendations on pembrolizumab (Keytruda) for relapsed or refractory classical Hodgkin lymphoma in people 3 years and over.

  12. Esketamine nasal spray for treatment-resistant depression (TA854)

    Evidence-based recommendations on esketamine (Spravato) for treatment-resistant depression in adults.

  13. Molnupiravir for treating COVID-19 (TA1056)

    Evidence-based recommendations on molnupiravir (Lagevrio) for treating mild to moderate COVID-19 in adults who have a positive SARS-CoV-2 test.

  14. Eladocagene exuparvovec for treating aromatic L-amino acid decarboxylase deficiency (HST26)

    Evidence-based recommendations on eladocagene exuparvovec (Upstaza) for treating aromatic L-amino acid decarboxylase deficiency in people 18 months and over.